1Friend M, Vucenik I, Miller M. Research pointers: Platelet responsiveness to aspirin in patients with hyperlipidaemia. BMJ, 2003, 326:82 - 83.
2Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease.Am J Cardiol, 2001, 88:230 -235.
3Nicholson NS, Panzer-Knodle SG, Haas NF, et al. Assessment of platelet function assays. Am Heart J, 1998, 135:S170 - S178.
4Chen WH, Lee PY, Ng W, et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol, 2004, 43:1122 - 1126.
5Wang JC, Aucoin-Barry D, Manuelian D, et al. Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function AssayASA. Am J Cardiol, 2003, 92:1492 - 1494.
6Bruno A, McConnell JP, Mansbach H, et al. Aspirin and urinary 11-dehydrothromboxane B2 in African American stroke patients.Stroke, 2002, 33:57 -60.
8Hennekens CH, Schror K, Weisman S, et al. Terms and conditions:semantic complexity and aspirin resistance. Circulation, 2004, 110:1706 - 1708.
9Antithrombotic Trialists′ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 2002, 324:71-86.
10Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost, 2003, 1:1710 - 1713.
